Targacept (TRGT) 0.96 $TRGT
nLife Therapeutics appoints Dr. Errol B. De Souza as Executive Chairman
GlobeNewswire - Wed Jun 01, 4:11AM CDT
nLife Therapeutics, an early-stage biopharmaceutical company leading developments in conjugated nucleic acids as therapeutic agents for central nervous system (CNS) and neuromuscular (NS) disorders, today announced the appointment of Dr. Errol B. De Souza, Ph.D. as executive chairman.
NBIX: 48.38 (-1.49), TRGT: 0.96 (-1.25), CBIO: 1.81 (-0.07), PTN: 0.49 (-0.01), IDXX: 88.88 (-1.37), BIOD: 0.34 (unch)
Catalyst Biosciences Completes Merger With Targacept and Creates a Protease-Based Hemostasis and Anti-Complement Company
GlobeNewswire - Thu Aug 20, 3:05PM CDT
Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions, today announced the completion of its merger with Targacept, Inc. (NASDAQ:TRGT, through August 20), effective as of August 20, 2015.
TRGT: 0.96 (-1.25), CBIO: 1.81 (-0.07)
Targacept Announces Stockholder Approval of Proposals Related to Merger with Catalyst Biosciences
BusinessWire - Tue Aug 18, 3:30PM CDT
Targacept, Inc. (NASDAQ: TRGT) today announced that its stockholders have voted to approve the adoption of the agreement and plan of merger, dated March 5, 2015, as amended May 6, 2015, and May 13, 2015, providing for the merger of a wholly-owned subsidiary of the company with Catalyst Biosciences, Inc., at its 2015 annual stockholders meeting held today.
TRGT: 0.96 (-1.25)
Targacept Declares Pre-closing Dividend in Connection with its Merger with Catalyst Biosciences, Inc.
BusinessWire - Tue Aug 04, 3:50PM CDT
Targacept, Inc. (NASDAQ: TRGT) announced today that its board of directors has declared a pre-closing dividend, in connection with its merger with Catalyst Biosciences, Inc., of an aggregate cash amount of $19,500,000, which is approximately $0.5686 per share, and non-interest bearing, redeemable convertible notes with an aggregate principal amount of $37,000,000, which is approximately $1.079 per share. Subject to the approvals described below, the pre-closing dividend will be paid on August 19, 2015 to Targacept's stockholders of record as of the close of business on August 14, 2015.
TRGT: 0.96 (-1.25)
Diabetic Gastroparesis Therapeutics Pipeline Review, H1 2015 - 7 Companies & 10 Drug Profiles
M2 - Thu Jun 11, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cxgxkz/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cempra, Inc. - Evoke Pharma, Inc. - GlaxoSmithKline plc - Ironwood Pharmaceuticals, Inc. - Rhythm Pharmaceuticals - Shire Plc - Targacept, Inc. Drug Profiles - camicinal - ETX-101 - ETX-301 - IW-9179 - metoclopramide hydrochloride - prucalopride succinate - relamorelin - Small Molecules to Agonize Motilin Receptor for GERD and Diabetic Gastroparesis - TC-6499 - velusetrag For more information visit http://www.researchandmarkets.com/research/cxgxkz/diabetic
EVOK: 5.26 (-0.04), IRWD: 12.87 (-0.13), TRGT: 0.96 (-1.25), SHPG: 177.10 (-6.85), GSK: 40.93 (-1.13), CEMP: 18.72 (-0.14)
Dyskinesia - Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2wzs3f/dyskinesia) has announced the addition of the "Dyskinesia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Adamas Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advicenne Pharma - Amarantus Bioscience Holdings, Inc. - Astraea Therapeutics, LLC - Auspex Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Catalyst Pharmaceutical Partners, Inc. - Contera Pharma ApS - EpiVax, Inc. - Heptares Therapeutics Ltd. - Integrative Research Laboratories Sweden AB - Ipsen S.A. - Medicure Inc. - Medy-Tox Inc. - Merz Pharmaceuticals GmbH - Neurim Pharmaceuticals Ltd - Neurocrine Biosciences, Inc. - Neurolixis Inc. - Novartis AG - Osmotica Pharmaceutical Corp. - Otsuka Holdings Co., Ltd. - Santhera Pharmaceuticals Holding AG - SciFluor Life Sciences, LLC - Synchroneuron Inc. - Targacept, Inc. - Upsher-Smith Laboratories, Inc. For more information visit http://www.researchandmarkets.com/research/2wzs3f/dyskinesia
NBIX: 48.38 (-1.49), BMRN: 81.10 (-1.84), TRGT: 0.96 (-1.25), CPRX: 0.62 (-0.03), ASPX: 100.96 (unch), NVS: 78.94 (-1.57)
Targacept and Catalyst Biosciences Amend Definitive Merger Agreement
BusinessWire - Thu May 14, 7:38AM CDT
Targacept, Inc. (NASDAQ: TRGT) and Catalyst Biosciences, Inc., a privately held biopharmaceutical company, jointly announced that they have entered into an amendment to the definitive agreement to merge the two companies. Targacept and Catalyst previously announced entering into the definitive merger agreement on March 5, 2015. On April 6, 2015, Targacept disclosed the termination, effective June 1, 2015, of the research and license agreement between Catalyst and Wyeth LLC (a wholly owned subsidiary of Pfizer), which governs the development and commercialization of Catalyst's lead product candidate CB 813d/PF-05280602, an engineered Factor VIIa in development for severe hemophilia A and B. The amended agreement between Targacept and Catalyst considers the effect on the combined company of the termination of Catalyst's research and license agreement with Wyeth.
TRGT: 0.96 (-1.25)
Addiction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mhcllx/addiction) has announced the addition of the "Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acura Pharmaceuticals, Inc. - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - Beech Tree Labs, Inc. - BioDelivery Sciences International, Inc. - Bionex Pharmaceuticals LLC - Eli Lilly and Company - Embera NeuroTherapeutics, Inc. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Grunenthal GmbH - Heptares Therapeutics Ltd. - Immunovaccine, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Invion Limited - Johnson & Johnson - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Selecta Biosciences, Inc. - SK Biopharmaceuticals Co., Ltd. - Sun Pharma Advanced Research Company Ltd. - Targacept, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mhcllx/addiction
BDSI: 2.67 (-0.18), PFE: 35.29 (-0.02), LLY: 73.95 (-0.48), GSK: 40.93 (-1.13), ACUR: 2.12 (-0.26), JNJ: 117.01 (+0.01), INSY: 13.99 (-2.04), TRGT: 0.96 (-1.25), GILD: 84.45 (-1.32), AZN: 27.97 (-0.99), ABBV: 61.00 (+0.25), ARNA: 1.99 (-0.07)
Targacept, Inc. - Product Pipeline Review - 2014
M2 - Mon Apr 20, 3:19AM CDT
Product Pipeline Review - 2014
TRGT: 0.96 (-1.25)
Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 6:36PM CDT
Targacept, Inc. announced disappointing top-line data from a phase I/II exploratory study on its candidate TC-6499 for the treatment of diabetic gastroparesis.
CYTK: 8.21 (-0.09), VRX: 24.14 (-1.34), TRGT: 0.96 (-1.25), PFE: 35.29 (-0.02)
Targacept Announces Negative Top-Line Results from Exploratory Study of TC-6499 in Diabetic Gastroparesis
BusinessWire - Thu Apr 16, 7:30AM CDT
Targacept, Inc. (NASDAQ: TRGT) today announced top-line results from a Phase 1/2 exploratory study of TC-6499 as a treatment for diabetic gastroparesis, a chronic disorder that slows or stops the passage of food from the stomach to the small intestine. In the trial, TC-6499 did not meet the primary endpoint of the study, change in gastric emptying half-time (BT_t1/2), as measured by a carbon ((13)C) labeled gastric emptying breath test, relative to placebo.
TRGT: 0.96 (-1.25)
BUYINS.NET: SIRO, TRGT, SBGI, EMR, MDC, HEP Expected To Be Up Before Next Earnings Releases
M2 - Wed Apr 15, 6:13AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and December earnings reports. Sirona Dental Systems Inc (NASDAQ:SIRO), Targacept Inc (NASDAQ:TRGT), Sinclair Broadcast Group Inc (NASDAQ:SBGI), Emerson Electric Co (NYSE:EMR), MDC Holdings Inc (NYSE:MDC), Holly Energy Partners LP (NYSE:HEP) are all expected to be Up Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com . The following stocks are expected to go Up Before earnings are released Friday:
HEP: 34.09 (-0.22), SIRO: 109.97 (-0.13), MDC: 23.96 (-0.59), TRGT: 0.96 (-1.25), EMR: 52.73 (-0.86), SBGI: 31.18 (-0.65)
The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead
GILD: 84.45 (-1.32), TRGT: 0.96 (-1.25), JUNO: 42.98 (-2.55), RGLS: 5.27 (-0.07), ALKS: 42.65 (-1.17)
Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 08, 1:53PM CDT
With first quarter earnings season yet to start, it was a relatively slow week for the biotech sector.
GILD: 84.45 (-1.32), TRGT: 0.96 (-1.25), AMGN: 154.78 (-2.00), JUNO: 42.98 (-2.55), RGLS: 5.27 (-0.07), ALKS: 42.65 (-1.17), CELG: 102.91 (-3.22)
Targacept Crumbles as Pfizer Pulls Out of Collaboration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 07, 2:30PM CDT
Targacept (TRGT) crumbled after Catalyst informed that Pfizer (PFE) will be terminating its agreement with Catalyst Biosciences.
TRGT: 0.96 (-1.25), PFE: 35.29 (-0.02), AZN: 27.97 (-0.99), AFFX: 14.01 (+0.02)
Nasdaq stocks posting largest volume increases
AP - Wed Mar 25, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
WBB: 19.79 (-0.02), OTIV: 1.01 (+0.02), TRGT: 0.96 (-1.25), SEED: 1.72 (-0.03), ORMP: 8.23 (-0.32), FCAP: 31.59 (+0.08), ASUR: 4.53 (-0.26), LIME: 2.17 (-0.21), KRFT: 88.19 (-0.11), VBLT: 4.90 (+0.10), FNJN: 1.69 (-0.06), DGLY: 3.65 (-0.07), KFX: 11.01 (+0.02)
nLife Therapeutics appoints Dr. Errol B. De Souza as Executive Chairman
GlobeNewswire - Wed Jun 01, 4:11AM CDT
nLife Therapeutics, an early-stage biopharmaceutical company leading developments in conjugated nucleic acids as therapeutic agents for central nervous system (CNS) and neuromuscular (NS) disorders, today announced the appointment of Dr. Errol B. De Souza, Ph.D. as executive chairman.
NBIX: 48.38 (-1.49), TRGT: 0.96 (-1.25), CBIO: 1.81 (-0.07), PTN: 0.49 (-0.01), IDXX: 88.88 (-1.37), BIOD: 0.34 (unch)
Catalyst Biosciences Completes Merger With Targacept and Creates a Protease-Based Hemostasis and Anti-Complement Company
GlobeNewswire - Thu Aug 20, 3:05PM CDT
Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions, today announced the completion of its merger with Targacept, Inc. (NASDAQ:TRGT, through August 20), effective as of August 20, 2015.
TRGT: 0.96 (-1.25), CBIO: 1.81 (-0.07)
Targacept Announces Stockholder Approval of Proposals Related to Merger with Catalyst Biosciences
BusinessWire - Tue Aug 18, 3:30PM CDT
Targacept, Inc. (NASDAQ: TRGT) today announced that its stockholders have voted to approve the adoption of the agreement and plan of merger, dated March 5, 2015, as amended May 6, 2015, and May 13, 2015, providing for the merger of a wholly-owned subsidiary of the company with Catalyst Biosciences, Inc., at its 2015 annual stockholders meeting held today.
TRGT: 0.96 (-1.25)
Targacept Declares Pre-closing Dividend in Connection with its Merger with Catalyst Biosciences, Inc.
BusinessWire - Tue Aug 04, 3:50PM CDT
Targacept, Inc. (NASDAQ: TRGT) announced today that its board of directors has declared a pre-closing dividend, in connection with its merger with Catalyst Biosciences, Inc., of an aggregate cash amount of $19,500,000, which is approximately $0.5686 per share, and non-interest bearing, redeemable convertible notes with an aggregate principal amount of $37,000,000, which is approximately $1.079 per share. Subject to the approvals described below, the pre-closing dividend will be paid on August 19, 2015 to Targacept's stockholders of record as of the close of business on August 14, 2015.
TRGT: 0.96 (-1.25)
Diabetic Gastroparesis Therapeutics Pipeline Review, H1 2015 - 7 Companies & 10 Drug Profiles
M2 - Thu Jun 11, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cxgxkz/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cempra, Inc. - Evoke Pharma, Inc. - GlaxoSmithKline plc - Ironwood Pharmaceuticals, Inc. - Rhythm Pharmaceuticals - Shire Plc - Targacept, Inc. Drug Profiles - camicinal - ETX-101 - ETX-301 - IW-9179 - metoclopramide hydrochloride - prucalopride succinate - relamorelin - Small Molecules to Agonize Motilin Receptor for GERD and Diabetic Gastroparesis - TC-6499 - velusetrag For more information visit http://www.researchandmarkets.com/research/cxgxkz/diabetic
EVOK: 5.26 (-0.04), IRWD: 12.87 (-0.13), TRGT: 0.96 (-1.25), SHPG: 177.10 (-6.85), GSK: 40.93 (-1.13), CEMP: 18.72 (-0.14)
Dyskinesia - Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2wzs3f/dyskinesia) has announced the addition of the "Dyskinesia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Adamas Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advicenne Pharma - Amarantus Bioscience Holdings, Inc. - Astraea Therapeutics, LLC - Auspex Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Catalyst Pharmaceutical Partners, Inc. - Contera Pharma ApS - EpiVax, Inc. - Heptares Therapeutics Ltd. - Integrative Research Laboratories Sweden AB - Ipsen S.A. - Medicure Inc. - Medy-Tox Inc. - Merz Pharmaceuticals GmbH - Neurim Pharmaceuticals Ltd - Neurocrine Biosciences, Inc. - Neurolixis Inc. - Novartis AG - Osmotica Pharmaceutical Corp. - Otsuka Holdings Co., Ltd. - Santhera Pharmaceuticals Holding AG - SciFluor Life Sciences, LLC - Synchroneuron Inc. - Targacept, Inc. - Upsher-Smith Laboratories, Inc. For more information visit http://www.researchandmarkets.com/research/2wzs3f/dyskinesia
NBIX: 48.38 (-1.49), BMRN: 81.10 (-1.84), TRGT: 0.96 (-1.25), CPRX: 0.62 (-0.03), ASPX: 100.96 (unch), NVS: 78.94 (-1.57)
Targacept and Catalyst Biosciences Amend Definitive Merger Agreement
BusinessWire - Thu May 14, 7:38AM CDT
Targacept, Inc. (NASDAQ: TRGT) and Catalyst Biosciences, Inc., a privately held biopharmaceutical company, jointly announced that they have entered into an amendment to the definitive agreement to merge the two companies. Targacept and Catalyst previously announced entering into the definitive merger agreement on March 5, 2015. On April 6, 2015, Targacept disclosed the termination, effective June 1, 2015, of the research and license agreement between Catalyst and Wyeth LLC (a wholly owned subsidiary of Pfizer), which governs the development and commercialization of Catalyst's lead product candidate CB 813d/PF-05280602, an engineered Factor VIIa in development for severe hemophilia A and B. The amended agreement between Targacept and Catalyst considers the effect on the combined company of the termination of Catalyst's research and license agreement with Wyeth.
TRGT: 0.96 (-1.25)
Addiction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mhcllx/addiction) has announced the addition of the "Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acura Pharmaceuticals, Inc. - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - Beech Tree Labs, Inc. - BioDelivery Sciences International, Inc. - Bionex Pharmaceuticals LLC - Eli Lilly and Company - Embera NeuroTherapeutics, Inc. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Grunenthal GmbH - Heptares Therapeutics Ltd. - Immunovaccine, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Invion Limited - Johnson & Johnson - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Selecta Biosciences, Inc. - SK Biopharmaceuticals Co., Ltd. - Sun Pharma Advanced Research Company Ltd. - Targacept, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mhcllx/addiction
BDSI: 2.67 (-0.18), PFE: 35.29 (-0.02), LLY: 73.95 (-0.48), GSK: 40.93 (-1.13), ACUR: 2.12 (-0.26), JNJ: 117.01 (+0.01), INSY: 13.99 (-2.04), TRGT: 0.96 (-1.25), GILD: 84.45 (-1.32), AZN: 27.97 (-0.99), ABBV: 61.00 (+0.25), ARNA: 1.99 (-0.07)
Targacept, Inc. - Product Pipeline Review - 2014
M2 - Mon Apr 20, 3:19AM CDT
Product Pipeline Review - 2014
TRGT: 0.96 (-1.25)
Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 6:36PM CDT
Targacept, Inc. announced disappointing top-line data from a phase I/II exploratory study on its candidate TC-6499 for the treatment of diabetic gastroparesis.
CYTK: 8.21 (-0.09), VRX: 24.14 (-1.34), TRGT: 0.96 (-1.25), PFE: 35.29 (-0.02)
Targacept Announces Negative Top-Line Results from Exploratory Study of TC-6499 in Diabetic Gastroparesis
BusinessWire - Thu Apr 16, 7:30AM CDT
Targacept, Inc. (NASDAQ: TRGT) today announced top-line results from a Phase 1/2 exploratory study of TC-6499 as a treatment for diabetic gastroparesis, a chronic disorder that slows or stops the passage of food from the stomach to the small intestine. In the trial, TC-6499 did not meet the primary endpoint of the study, change in gastric emptying half-time (BT_t1/2), as measured by a carbon ((13)C) labeled gastric emptying breath test, relative to placebo.
TRGT: 0.96 (-1.25)
BUYINS.NET: SIRO, TRGT, SBGI, EMR, MDC, HEP Expected To Be Up Before Next Earnings Releases
M2 - Wed Apr 15, 6:13AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and December earnings reports. Sirona Dental Systems Inc (NASDAQ:SIRO), Targacept Inc (NASDAQ:TRGT), Sinclair Broadcast Group Inc (NASDAQ:SBGI), Emerson Electric Co (NYSE:EMR), MDC Holdings Inc (NYSE:MDC), Holly Energy Partners LP (NYSE:HEP) are all expected to be Up Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com . The following stocks are expected to go Up Before earnings are released Friday:
HEP: 34.09 (-0.22), SIRO: 109.97 (-0.13), MDC: 23.96 (-0.59), TRGT: 0.96 (-1.25), EMR: 52.73 (-0.86), SBGI: 31.18 (-0.65)
The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead
GILD: 84.45 (-1.32), TRGT: 0.96 (-1.25), JUNO: 42.98 (-2.55), RGLS: 5.27 (-0.07), ALKS: 42.65 (-1.17)
Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 08, 1:53PM CDT
With first quarter earnings season yet to start, it was a relatively slow week for the biotech sector.
GILD: 84.45 (-1.32), TRGT: 0.96 (-1.25), AMGN: 154.78 (-2.00), JUNO: 42.98 (-2.55), RGLS: 5.27 (-0.07), ALKS: 42.65 (-1.17), CELG: 102.91 (-3.22)
Targacept Crumbles as Pfizer Pulls Out of Collaboration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 07, 2:30PM CDT
Targacept (TRGT) crumbled after Catalyst informed that Pfizer (PFE) will be terminating its agreement with Catalyst Biosciences.
TRGT: 0.96 (-1.25), PFE: 35.29 (-0.02), AZN: 27.97 (-0.99), AFFX: 14.01 (+0.02)
Nasdaq stocks posting largest volume increases
AP - Wed Mar 25, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
WBB: 19.79 (-0.02), OTIV: 1.01 (+0.02), TRGT: 0.96 (-1.25), SEED: 1.72 (-0.03), ORMP: 8.23 (-0.32), FCAP: 31.59 (+0.08), ASUR: 4.53 (-0.26), LIME: 2.17 (-0.21), KRFT: 88.19 (-0.11), VBLT: 4.90 (+0.10), FNJN: 1.69 (-0.06), DGLY: 3.65 (-0.07), KFX: 11.01 (+0.02)
